Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBF-680 crossover allergen challenge study in controlled asthma
2015-001957-34Phase 2Terminated
- Sponsor
- Palobiofarma
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PBF-680 in asthma (2 arms), sponsored by Palobiofarma. Primary endpoint: 4-10 hour post-allergen bronchoprovocation FEV1-fall AUC. Started Oct 2015; status: terminated.
02
Drugs
PBF-680
03
Conditions
asthma
Beyond the preview
Go deeper on 2015-001957-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001957-34.